Malignancies associated with systemic lupus erythematosus in Taiwan: a nationwide population-based cohort study

被引：0
作者：
Ji-An Liang
Li-Min Sun
Jun-Jun Yeh
Wan-Yu Lin
Shih-Ni Chang
Hung-Chang Sung
Chia-Hung Kao
机构：
[1] China Medical University Hospital,Department of Radiation Oncology
[2] China Medical University,School of Medicine, College of Public Health
[3] Zuoying Armed Forces General Hospital,Department of Radiation Oncology
[4] Pingtung Christian Hospital and MeiHo University,Department of Nuclear Medicine
[5] Taichung Veterans General Hospital,Institute of Radiological Science
[6] Central Taiwan University of Science and Technology,Management Office for Health Data
[7] China Medical University Hospital,Institute of Environmental Health, College of Public Health
[8] China Medical University,Department of Nuclear Medicine and PET Center
[9] China Medical University Hospital,undefined
来源：
Rheumatology International | 2012年 / 32卷
关键词：
Malignancy; Systemic lupus erythematosus; Prostate cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Patients with systemic lupus erythematosus (SLE) are suggestive to have a higher cancer risk. The aim of this study is to evaluate the possible association of malignancy and SLE in Taiwan. We used the data of the National Health Insurance system of Taiwan to assess this issue. The SLE cohort contained 2,150 patients, and each patient was randomly frequency matched to 8 people without SLE on age and sex. The Cox’s proportion hazard regression analysis was conducted to estimate the effects of SLE on the cancer risk. In patients with SLE, the risk of developing overall cancer was marginally significantly higher [adjusted Hazard ratio (HR) = 1.26, 95% confidence interval (95% CI) = 0.99–1.59] and was significantly higher for developing prostate cancer (adjusted HR = 3.78, 95% CI = 1.30–11.0). Our study unexpectedly found that Taiwanese patients with SLE have a higher risk to develop prostate cancer.
引用
收藏
页码：773 / 778
页数：5
相关论文
共 112 条
[1]  
Abu-Shakra M(1995)Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality J Rheumatol 22 1265-1270
[2]  
Urowitz MB(2001)Systemic lupus erythematosus Lancet 357 1027-1032
[3]  
Gladman DD(2007)Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual Lupus 16 309-317
[4]  
Gough J(2005)An international cohort study of cancer in systemic lupus erythematosus Arthritis Rheum 52 1481-1490
[5]  
Ruiz-Irastorza G(2002)Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus Scand J Rheumatol 31 66-71
[6]  
Khamashta MA(1997)Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus Arthritis Rheum 40 761-768
[7]  
Castellino G(2010)Malignancies in systemic lupus erythematosus Autoimmun Rev 9 195-199
[8]  
Hughes GR(2003)Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus Lupus 12 687-691
[9]  
Nossent J(2001)Systemic lupus erythematosus and the risk of malignancy Lupus 10 394-400
[10]  
Cikes N(1996)Malignancy in systemic lupus erythematosus Arthritis Rheum 39 1050-1054
12345678910